3 completed, 3 unknown, 2 recruiting, 1 terminated. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 3, Unknown 3, Recruiting 2, Terminated 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow CART-19: new trials by email Literature Review of CART-19 trials Research Report on CART-19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma CART-19 - Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | University of Sao Paulo | 81 | 2024-03-21 | 2024-12-09 |
| CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) CART-19 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 15 | 2017-10-18 | 2023-11-29 |
| The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma Cyclophosphamide, Fludarabine, CART-19 - B Cell Lymphoma | Phase 1 | Unknown | Henan Cancer Hospital | 30 | 2016-08-01 | 2017-04-05 |
| Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia CART-19 - Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Beijing Sanwater Biological Technology Co., Ltd. | 20 | 2016-05-01 | 2016-10-14 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2015-12-16 | 2022-06-30 |
| Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma CART-19 - B Cell Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 73 | 2011-08-17 | 2020-03-23 |
| Allo CART-19 Protocol CART-19 - Acute Lymphocytic Leukemia | Phase 1 | Terminated | University of Pennsylvania | 2 | 2010-09-01 | 2020-07-09 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy CART-19 - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | University of Pennsylvania | 26 | 2010-03-17 | 2023-06-22 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Hematologic Neoplasms (1) · Leukemia, B-Cell (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Neoplasm, Residual (1)
University of Pennsylvania (3) · Beijing Sanwater Biological Technology Co., Ltd. (1) · Henan Cancer Hospital (1) · M.D. Anderson Cancer Center (1) · Nathan Denlinger (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1) · University of Sao Paulo (1)
United States (5) · China (3) · Brazil (1)
David Porter, MD (1) · Diego V Cle, MD, PhD, MBA (1) · Nathan Denlinger, DO (1) · Noelle Frey, MD (1) · Partow Kebriaei (1) · Stephan A Grupp, MD,PhD (1) · Xiaowen Tang, Ph.D. (1) · Yongping Song (1)
PMID 25317870, PMID 27632680, PMID 30178481, PMID 31076448, PMID 31815579